In the BioHarmony Drug Report Database
Pralsetinib
Gavreto (pralsetinib) is a small molecule pharmaceutical. Pralsetinib was first approved as Gavreto on 2020-09-04. It is used to treat non-small-cell lung carcinoma in the USA. The pharmaceutical is active against proto-oncogene tyrosine-protein kinase receptor Ret. In addition, it is known to target vascular endothelial growth factor receptor 2. Gavreto’s patent is valid until 2036-11-01 (FDA).
Trade Name
|
Gavreto |
|---|---|
Common Name
|
pralsetinib |
ChEMBL ID
|
CHEMBL4582651 |
Indication
|
non-small-cell lung carcinoma |
Drug Class
|
Tyrosine kinase inhibitors |
Image (chem structure or protein)